ARDS — Aridis Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.01m
- -$0.03m
- $3.09m
U.S. STOCKS ON THE MOVE-Xerox, AC Immune, OpGen
U.S. STOCKS ON THE MOVE-Tesla, Aridis Pharmaceuticals, BuzzFeed
Aridis falls after lung infection drug fails to meet efficacy goal
Brief: Aridis Reports Top-Line Results Of Late-Stage Trial Of Ventilator Associated Pneumonia
Brief: Aridis Pharmaceuticals Provides AR 501 Phase 2 Trial Update
Brief: Aridis Pharmaceuticals To Discuss Topline Data From Phase 3 Study Of Ar-301 On Call On January 25
Brief: Aridis Pharmaceuticals Receives Equity Investment From The Cystic Fibrosis Foundation
Brief: Aridis Receives Equity Investment From The Cystic Fibrosis Foundation
Brief: Aridis Pharmaceuticals Files Prospectus Relates To Resale By A Certain Selling Stockholder Of Up To 7.2 Mln Shares Of Common Stock
Brief: Aridis Signs Exclusive Terms To Secure Worldwide Commercial Licenses For Pan-Ebola And Pan-Marburg Monoclonal Antibody Programs From Mapp Biopharmaceutical
Brief: Aridis Closes Patient Enrollment In Phase 2A Study Of Ar-501 In Cystic Fibrosis
Brief: Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results
Aridis Pharmaceuticals Inc expected to post a loss of 17 cents a share - Earnings Preview
Brief: Aridis Pharmaceuticals - Got Written Notification From Nasdaq Indicating Failure To Satisfy A Continued Listing Rule
Brief: Aridis Announces The Closing Of Patient Enrollment In The Ar-301 Global Phase 3 Superiority Study
Brief: Aridis Pharmaceuticals Withdraws Public Offering Of Common Stock
Aridis soars after scrapping stock offering
Brief: Aridis Pharmaceuticals Announces Proposed Public Offering Of Common Stock
Brief: Aridis Pharmaceuticals Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing